Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events

P. Michael Ho, MD, PhD¹, Thomas M. Maddox, MD, SM¹, Colleen Ross, MS³, John S. Rumsfeld, MD, PhD¹, David J. Magid, MD, MPH²,³

1. Denver VA Medical Center
2. University of Colorado Denver
3. Institute for Health Research, Kaiser Permanente of Colorado

Corresponding author:
P. Michael Ho, MD, PhD
Email: Michael.ho@uchsc.edu

Short title: Chronotropic response in patients with diabetes

Received 26 March 2008 and accepted 7 May 2008.
**Objectives:** To assess the association between impaired chronotropic response (CR) and adverse events among patients with diabetes referred for exercise treadmill testing (ETT).

**Research design and methods:** Impaired CR was defined as achievement of less than 80% of a patient’s heart rate reserve. Multivariable Cox proportional hazards regression assessed the independent association between impaired CR and adverse outcomes adjusting for demographics, co-morbidities and treadmill variables including the Duke Treadmill score.

**Results:** Of 1,341 patients with diabetes, 35.7% (n=479) demonstrated impaired CR during ETT. Patients with impaired CR were at increased risk of all-cause mortality, myocardial infarction, or coronary revascularization procedures. In multivariable analyses, impaired CR remained significantly associated with adverse outcomes (HR 1.53; 95% CI 1.10-2.14).

**Conclusions:** Among patients with diabetes, impaired CR is common during ETT and is associated with adverse outcomes. Impaired CR can be used as another non-invasive tool to risk stratify patients with diabetes following ETT.
Impaired chronotropic response is defined as inability of the heart rate to increase normally with exercise and may be related to alterations in sympathetic and parasympathetic tone, as well as autonomic dysfunction (1). Impaired CR during exercise treadmill testing (ETT) is associated with increased risk of cardiac events and all-cause mortality (2-4). Patients with diabetes have a higher incidence of autonomic dysfunction and therefore impaired CR during ETT may identify patients with diabetes at risk for adverse outcomes (1). However, prior studies assessing the prognostic import of impaired CR have not specifically focused on this subgroup, have only included small numbers of patients with diabetes, or the association between impaired CR and adverse outcomes has been inconclusive among patients with diabetes (1,3,5). Therefore, the objective of this study was to assess the association between impaired CR and adverse events, including all-cause mortality, myocardial infarction, and coronary revascularization procedures among patients with diabetes referred for ETT in routine clinical practice.

METHODS:

Study population and data collection: We examined a consecutive, prospective cohort of patients (n=9,569) referred for ETT between July 2001 and June 2004. Details of this cohort have been previously described (6). All patients were enrolled in Kaiser Permanente of Colorado (KPCO), an integrated, nonprofit managed care organization that provides medical services to more than 475,000 members in the Denver, Colorado metropolitan area. Of these patients, 1,341 (14.0%) had diabetes and comprise the analytical cohort.

Prior to ETT, a structured history and medical record review were performed. Symptom-limited ETT was conducted according to standardized protocols, with the Bruce protocol used in 85% of tests. During each exercise and recovery stage, symptoms, blood pressure, heart rate, cardiac rhythm, and metabolic equivalents (METs) were recorded. The Duke Treadmill Score (DTS) was calculated using the total exercise time or energy expenditure, maximal ST-segment depression, and angina severity score (7). Only 35 patients had high-risk DTS (score < -10) and were excluded given the low likelihood that their clinical management would change by additional ETT information. For patients undergoing multiple treadmill tests during this period, only the first test was considered in the analyses.

Predictor Variable: Impaired CR was defined as achievement of less than 80% of a patient’s heart rate reserve (calculated as (220-age)-resting heart rate) at peak exercise or less than 62% for patients taking β-blockers within 72 hours of ETT (2).

Outcome Variables: The primary outcome of interest was the combined endpoint of all-cause mortality, hospitalization for acute myocardial infarction (MI), or receipt of coronary revascularization procedure (either coronary artery bypass graft surgery (CABG) or percutaneous intervention (PCI)). All-cause mortality was determined from KPCO databases and validated by comparison with State of Colorado death certificates. Data on acute MI hospitalizations and coronary revascularization procedures within and outside of the KPCO system were identified from KPCO databases. Follow-up and vital status information was available after the exercise test on 99% of patients through October 31, 2005.

Statistical Analysis: Baseline characteristics were compared between diabetes patients with or without impaired CR. Freedom from events by CR category was graphically represented by Kaplan-Meier curves and compared with the log-rank test.
Multivariable Cox proportional hazards models assessed the independent association between impaired CR and outcomes. Variables entered into the multivariable models included demographic factors (age, sex), clinical factors (smoking status, history of coronary artery disease, cerebral vascular disease, peripheral vascular disease, cancer, chronic obstructive pulmonary disease, obstructive sleep apnea, diabetes mellitus, hypertension, lipid disorders, depression, congestive heart failure) and treadmill variables (DTS, abnormal heart rate recovery, ventricular ectopy in recovery). We also stratified our cohort into low or intermediate-risk DTS and repeated the analyses assessing the association between impaired CR and adverse outcomes. The Cox proportional hazards assumption was verified for all models by calculating and graphing Schoenfeld residuals by survival time.

The study was approved by the Kaiser Permanente Colorado Institutional Review Board.

RESULTS:
Greater than one-third of patients with diabetes (35.7%; n=479) demonstrated impaired CR during ETT. Patients with impaired CR were more likely to have co-morbid conditions (e.g., hypertension, coronary artery disease, peripheral vascular disease, congestive heart failure) and abnormal heart rate recovery during ETT. In addition, patients with impaired CR, compared to patients with normal CR, were at increased risk of adverse outcomes including all-cause mortality (4.2% vs. 1.9%; p=0.02), myocardial infarction (3.3% vs. 1.7%; p=0.06), and revascularization procedures (23.8% vs. 11.7%; p<0.01) (Figure 1).

In multivariable analyses, impaired CR remained significantly associated with increased risk of adverse outcomes, including all-cause mortality, MI, or revascularization procedures (HR 1.53; 95% CI 1.10-2.14). In stratified analyses, the association between impaired CR and adverse outcomes demonstrated a similar trend for patients with low (HR 1.36; 95% CI 0.85-2.20) or intermediate (HR 1.95; 95% CI 1.15-3.31) risk DTS.

CONCLUSIONS:
In a community based cohort of patients with diabetes referred for ETT, impaired CR was common and associated with adverse outcomes even after adjusting for the Duke Treadmill Score. These findings add to the literature by demonstrating the prognostic utility of impaired CR during ETT among patients with diabetes and complement the prior work on impaired CR and outcomes in the general population of patients referred for ETT. Together, these studies support the use of impaired CR as another non-invasive tool to risk stratify patients following ETT beyond the routine parameters of ST-segment change, presence of angina and treadmill exercise time. Additional studies are needed to determine whether the presence of impaired CR during ETT among patients with diabetes should lead to more aggressive medical therapy, additional non-invasive testing with imaging or invasive evaluation.

ACKNOWLEDGEMENTS:
This study was funded in part by CV Therapeutics, Inc. The sponsors were not directly involved in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation of the manuscript. Dr. Ho is supported by a VA Research & Development Career Development Award.
References:

Figure: Kaplan-Meier curve for freedom from adverse events (all-cause mortality, MI or revascularization procedures) between patients with and without impaired chronotropic response during exercise treadmill testing.